公开(公告)号：US11831272B2

公开(公告)日：2023-11-28

申请号：US17396110

申请日：2021-08-06

申请人： The Regents of the University of Michigan

发明人： Max Shtein ,  Erin Evke ,  Michael Arwashan ,  Chao Huang

IPC分类号： H02S20/32 ,  F24S50/80 ,  F24S50/20 ,  F24S30/00

CPC分类号： H02S20/32 ,  F24S50/20 ,  F24S50/80 ,  F24S2030/10

摘要： A device includes a support structure having a plurality of concentric cuts through the support structure that define a set of structure sections. The device also includes an insert assembly supported by the support structure at an inner structure section of the set of structure sections. The inner structure section is configured to tilt the insert assembly at a tilt angle in accordance with a displacement of a first outer structure section of the set of structure sections.

公开(公告)号：US20230374017A1

公开(公告)日：2023-11-23

申请号：US18017108

申请日：2021-07-21

申请人： The Regents of the University of Michigan

发明人： CAGRI BESIRLI ,  JASON RECH ,  THOMAS WUBBEN ,  BRENNAN WATCH

IPC分类号： C07D487/04 ,  C07D519/00 ,  C07D495/14 ,  C07D471/14 ,  C07D513/14 ,  C07D498/14

CPC分类号： C07D487/04 ,  C07D519/00 ,  C07D495/14 ,  C07D471/14 ,  C07D513/14 ,  C07D498/14

摘要： Provided herein are compositions and methods for activating pyruvate kinase (e.g., in a subject). In particular, provided herein are compositions and methods for treating a disease or condition (e.g., eye disease, blood disorders, or cancer) using pyruvate kinase activators.

公开(公告)号：US11825687B2

公开(公告)日：2023-11-21

申请号：US16925777

申请日：2020-07-10

申请人： The Regents of the University of Michigan ,  The University of Southern California

发明人： Stephen R. Forrest ,  Yue Qu ,  Haonan Zhao ,  Mark E. Thompson

IPC分类号： H10K50/852 ,  C09K11/06 ,  H10K50/11 ,  H10K85/30 ,  H10K101/10 ,  H10K50/13 ,  H10K50/854 ,  H10K59/32 ,  H10K101/30 ,  H10K102/00 ,  H10K59/90

CPC分类号： H10K50/852 ,  C09K11/06 ,  H10K50/11 ,  H10K85/371 ,  C09K2211/1029 ,  C09K2211/1044 ,  C09K2211/188 ,  H10K50/13 ,  H10K50/854 ,  H10K59/32 ,  H10K59/90 ,  H10K2101/10 ,  H10K2101/30 ,  H10K2102/00 ,  H10K2102/351

摘要： An OLED device comprises a substrate, a first electrode positioned over the substrate, a second electrode positioned over the first electrode, at least one emissive layer positioned between the first and second electrodes in a first region of the OLED device, and a multilayer dielectric reflector stack, comprising a plurality of dielectric reflector layers positioned between the substrate and the first electrode, wherein the multilayer dielectric reflector stack is configured to form an optical cavity with the emissive layer having a Purcell Factor of at least 3.

公开(公告)号：US11819712B2

公开(公告)日：2023-11-21

申请号：US17008369

申请日：2020-08-31

申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN

发明人： Charles A. Cain ,  Adam Maxwell ,  Zhen Xu ,  Kuang-Wei Lin

IPC分类号： A61N7/00 ,  A61B17/32

CPC分类号： A61N7/00 ,  A61B2017/320069 ,  A61N2007/003 ,  A61N2007/0039 ,  A61N2007/0065

摘要： Apparatus and methods are provided for applying ultrasound pulses into tissue or a medium in which the peak negative pressure (P−) of one or more negative half cycle(s) of the ultrasound pulses exceed(s) an intrinsic threshold of the tissue or medium, to directly form a dense bubble cloud in the tissue or medium without shock-scattering. In one embodiment, a microtripsy method of Histotripsy therapy comprises delivering an ultrasound pulse from an ultrasound therapy transducer into tissue, the ultrasound pulse having at least a portion of a peak negative pressure half-cycle that exceeds an intrinsic threshold in the tissue to produce a bubble cloud of at least one bubble in the tissue, and generating a lesion in the tissue with the bubble cloud. The intrinsic threshold can vary depending on the type of tissue to be treated. In some embodiments, the intrinsic threshold in tissue can range from 15-30 MPa.

公开(公告)号：US11813358B2

公开(公告)日：2023-11-14

申请号：US16893772

申请日：2020-06-05

申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN

发明人： Ayyalusamy Ramamoorthy ,  Thirupathi Ravula ,  Nathaniel Z. Hardin

IPC分类号： A61K9/127 ,  C08F220/18 ,  C08F8/32 ,  C08F8/02

CPC分类号： A61K9/1278 ,  A61K9/1273 ,  C08F8/02 ,  C08F8/32 ,  C08F220/1804

摘要： The disclosure generally relates to lipid nanodiscs, in particular to lipid nanodiscs formed from polymers. A lipid nanodisc according to the disclosure includes a lipid bilayer having a first hydrophilic face and a second hydrophilic face opposing the first hydrophilic face, and a hydrophobic edge between the opposing hydrophilic faces, and a polymer encircling the hydrophobic edge of the lipid bilayer. The polymer includes a first monomeric unit having a pendant hydrophobic group and a second monomeric unit having a backbone hydrophilic group. Methods of making and characterizing the lipid nanodiscs are also disclosed.

公开(公告)号：US20230357249A1

公开(公告)日：2023-11-09

申请号：US17924242

申请日：2021-05-14

申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN

发明人： Shaomeng Wang ,  Xin Han ,  Weiguo Xiang ,  Chong Qin ,  Tianfeng Xu ,  Lijie Zhao ,  Mingliang Wang ,  Rohan Rej

IPC分类号： C07D487/04 ,  C07D519/00

CPC分类号： C07D487/04 ,  C07D519/00

摘要： The present disclosure provides compounds represented by Formula I : A-L-B 1 I, and the salts or solvates thereof, wherein A, L, and B1 are as defined in the specification, ompounds having Formula I are androgen receptor degraders useful for the treatment of ancer and other diseases.

公开(公告)号：US20230348873A1

公开(公告)日：2023-11-02

申请号：US18021729

申请日：2021-08-17

申请人： The Regents of the University of Michigan

发明人： YUQING CHEN ,  JIE XU ,  JIFENG ZHANG ,  DONGSHAN YANG ,  LINYUAN MA

IPC分类号： C12N9/22 ,  C07K14/415 ,  C12N15/10

CPC分类号： C12N9/22 ,  C07K14/415 ,  C12N15/102 ,  C12N2310/20

摘要： Provided herein is technology relating to molecular biological manipulation of genes and genomes and particularly, but not exclusively, to CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) methods, compositions, systems, and kits for improved genetic editing.

公开(公告)号：US20230346943A1

公开(公告)日：2023-11-02

申请号：US17793806

申请日：2021-01-20

申请人： The Regents of the University of California ,  THE REGENTS OF THE UNIVERSITY OF MICHIGAN

发明人： Matthew Krummel ,  Seok Ki Choi ,  James R. Baker, JR.

IPC分类号： A61K41/00 ,  A61K49/00 ,  A61K47/54

CPC分类号： A61K41/0042 ,  A61K47/545 ,  A61K47/549 ,  A61K49/0002

摘要： Provided herein, inter alia, are methods and compositions useful for treating a disease.

公开(公告)号：US20230338492A1

公开(公告)日：2023-10-26

申请号：US18318912

申请日：2023-05-17

申请人： The Regents of the University of Michigan

发明人： Qiao Li

IPC分类号： A61P35/00 ,  A61K39/00 ,  C12N5/0784

CPC分类号： A61K39/001154 ,  A61P35/00 ,  C12N5/0639 ,  A61K45/06

摘要： The present invention relates to compositions, systems, kits, and methods for generating and using ALDH1 antigen-pulsed dendritic cells (DCs). In certain embodiments, initial DCs are pulsed in vitro with a composition comprising ALDH1A1 and/or ALDH1A3 immunogenic peptide(s) to generate ALDH1 antigen-pulsed DCs, wherein the composition is free of tumor cells, cell lysates, and full-length ALDH1 proteins. In some embodiments, the ALDH1 antigen-pulsed DCs are administered to a subject in order to at least partially treat cancer (e.g., to kill at least some cancer stem cells in the subject).

公开(公告)号：US20230330259A1

公开(公告)日：2023-10-19

申请号：US18313856

申请日：2023-05-08

申请人： The Regents of the University of Michigan

发明人： Anna A. Schwendeman ,  Yuqing Eugene Chen ,  Yanhong Guo ,  Jifeng Zhang ,  Wenmin Yuan ,  Emily Morin

IPC分类号： A61K47/69 ,  A61K9/51 ,  A61K49/00 ,  A61P9/00 ,  A61K45/06

CPC分类号： A61K47/6917 ,  A61K9/5169 ,  A61K49/008 ,  A61K49/0032 ,  A61P9/00 ,  A61K45/06 ,  A61K47/02

摘要： The present invention relates to nanoparticles complexed with therapeutic agents configured for treating cardiovascular related disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising synthetic HDL (sHDL) nanoparticles carrying therapeutic agents configured for treating cardiovascular related disorders, methods for synthesizing such sHDL nanoparticles, as well as systems and methods utilizing such sHDL nanoparticles (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutic agents, imaging agents, and/or targeting agents (e.g., in cardiovascular disease diagnosis and/or therapy, etc.))).